Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
honeybee venom · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| honeybee venom (Apitoxin (Korea) Apitox (USA)) | DRUG | multiple intradermal injections of 100 ug pure honeybee venom |
Honeybee venom is being studied for the treatment of osteoarthritis of the knee. It is an investigational small molecule therapy developed by Apimeds Pharmaceuticals US, Inc. The treatment is intended to address pain and inflammation associated with this condition, though it remains in clinical development and is not yet approved.
Honeybee venom is being developed by Apimeds Pharmaceuticals US, Inc., a company traded under the ticker APUS. The company is conducting clinical research to evaluate the therapy for osteoarthritis of the knee. As of the latest data, the drug is in Phase 2 development.
Honeybee venom is in Phase 2 clinical development for osteoarthritis of the knee. It is an investigational therapy, meaning it has not been approved by regulatory authorities. A Phase 2 trial has been completed, and the drug remains under evaluation for safety and efficacy.
Honeybee venom has one completed Phase 2 clinical trial identified as NCT00949754, titled 'Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation.' The study enrolled 40 participants in the United States, with a minimum age of 35 years, and included both sexes.
Honeybee venom is also known as Apitox. The clinical trial NCT00949754 refers to the treatment as Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation. Both names refer to the same investigational therapy being developed by Apimeds Pharmaceuticals US, Inc.